Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allergic urticaria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Allergic urticaria. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-022864-12 Sponsor Protocol Number: AA-10-1.01 Start Date*: 2011-04-20
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab ...
    Medical condition: Disease to be investigated: 12 patients with severe chronic urticaria (CU) with or without angioedema which continously need medical treatment As a control: 6 patients with atopy syndrome consisti...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009159 Chronic urticaria LLT
    12.1 10021247 Idiopathic urticaria LLT
    12.1 10003639 Atopic dermatitis LLT
    12.1 10031673 Other atopic dermatitis and related conditions LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012013-22 Sponsor Protocol Number: BILA-3009/PED Start Date*: 2009-12-09
    Sponsor Name:FAES FARMA S.A.
    Full Title: A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children from 2 to <12 Years of age with Allergic Rhinoconjunctivitis or Chronic Ur...
    Medical condition: Allergic Rhinoconjunctivitis and chronic urticaria
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001728 Allergic rhinoconjunctivitis LLT
    12.0 10009159 Chronic urticaria LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001313-26 Sponsor Protocol Number: MEIN/14/Bil-ARU/001 Start Date*: 2015-07-15
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA
    Full Title: Effects of Bilastine on F1 Simulator driving performance in patients affected by allergic rhinitis and/or urticaria
    Medical condition: allergic rhinitis (seasonal or perennial) and/or urticaria
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10039095 Rhinitis seasonal LLT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10039094 Rhinitis perennial PT
    19.0 100000004858 10009159 Chronic urticaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003011-26 Sponsor Protocol Number: BILA-4021/PED Start Date*: 2021-10-26
    Sponsor Name:FAES FARMA S.A.
    Full Title: A multicentre, open-label clinical trial to assess plasma levels and safety of bilastine in children from 2 to 5 years of age with seasonal and/or perennial allergic rhinoconjunctivitis or urticaria
    Medical condition: Allergic rhinoconjunctivitis. Urticaria.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10046735 Urticaria PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003506-27 Sponsor Protocol Number: BILA-3312/PED Start Date*: 2013-01-25
    Sponsor Name:FAES FARMA, S.A.
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and tolerability of 10 mg once daily bilastine in children from 2 to 11 years of age with e...
    Medical condition: Allergic Rhinoconjunctivitis and Chronic Urticaria
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) PT (Completed) PL (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000205-39 Sponsor Protocol Number: A00426 Start Date*: 2015-02-18
    Sponsor Name:UCB, Inc.
    Full Title: A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Year...
    Medical condition: Allergic Rhinitis Chronic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004870 10001738 Allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003458-28 Sponsor Protocol Number: A00423 Start Date*: 2015-02-18
    Sponsor Name:UCB, Inc.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With...
    Medical condition: Allergic Rhinitis Chronic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004870 10001738 Allergy LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000047-99 Sponsor Protocol Number: MK-0476P2181V1 Start Date*: 2007-03-06
    Sponsor Name:Tari Haahtela
    Full Title: Montelukast as a controller of atopic syndrome - MONTAS-study
    Medical condition: Allergic symptoms (rhinitis, conjunctivits, asthma, oral symptoms and atopic eczema) caused by pollen allergy to birch or timothy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    20.0 100000004858 10003641 Atopic eczema LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-003940-21 Sponsor Protocol Number: BILA-3918/PED Start Date*: 2019-01-11
    Sponsor Name:FAES FARMA, S.A.
    Full Title: A pilot, multicentre, single-blind, randomized, placebo-controlled, parallel-group clinical trial, to assess the safety of Bilastine treatment regarding psychomotor performance using a virtual real...
    Medical condition: Allergic rhinoconjunctivitis (both seasonal allergic rhinitis -SAR- and perennial allergic rhinitis -PAR-) and/or urticaria.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000149-42 Sponsor Protocol Number: SYN008-002 Start Date*: 2021-08-16
    Sponsor Name:Synermore Biologics Co., Ltd
    Full Title: A Phase 3, Randomized, Double-blind, Parallel group, Active Controlled Study to Compare the Efficacy and Safety of SYN008 to Xolair® in Adult Patients with Chronic Spontaneous Urticaria and Inadequ...
    Medical condition: Chronic spontaneous urticaria (Allergic asthma, Chronic rhinosinusitis with nasal polyps)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10080060 Chronic rhinosinusitis with nasal polyps PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007657-31 Sponsor Protocol Number: MIARCU 01/2008 Start Date*: 2008-06-23
    Sponsor Name:Charité-University Berlin
    Full Title: Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria
    Medical condition: Urticaria characterized by mast cell and histamine-dependent wheal and flair type-skin responses associated with severe pruritus. The disease is very common and not always easy to treat. Mainstay t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006921-14 Sponsor Protocol Number: AF-H-01 Start Date*: 2009-02-09
    Sponsor Name:ALK-Abelló Arzneimittel GmbH
    Full Title: A multicentre randomised Phase II clinical trial to demonstrate equivalent pharmacodynamic efficacy and tolerability of two updosing schedules for ALK-Flex SQ
    Medical condition: Grass pollen induced allergic rhinoconjunctivitis requiring treatment during the grass pollen season
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004422-50 Sponsor Protocol Number: DM03RUP/IV/05 Start Date*: 2006-01-11
    Sponsor Name:J.Uriach y Compania S.A.,
    Full Title: A placebo-controlled, double-blind, cross-over study with rupatadine 10 mg in 30 mosquito-bite allergic adult subjects Rupatadiini-antihistamiini hyttyspistoallergiassa
    Medical condition: mosquito-bite allergic adults
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-014582-51 Sponsor Protocol Number: MO-90020714 Start Date*: 2010-03-26
    Sponsor Name:Faculty of Medicine, Technische Universität München
    Full Title: Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levels
    Medical condition: Patients with severe Atopic dermatitis and total IgE-level > 700 IU/ml (potentially associated with bronchial asthma and/or allergic rhinitis)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10002198 Anaphylactic reaction LLT
    12.0 10040400 Serum sickness LLT
    12.0 10043554 Thrombocytopenia LLT
    12.0 10019211 Headache LLT
    12.0 10028810 Nasopharyngitis LLT
    12.0 10040753 Sinusitis LLT
    12.0 10022000 Influenza LLT
    12.0 10006451 Bronchitis LLT
    12.0 10017888 Gastroenteritis LLT
    12.0 10034835 Pharyngitis LLT
    12.0 10047461 Viral infection LLT
    12.0 10034844 Pharyngolaryngeal pain LLT
    12.0 10011224 Cough LLT
    12.0 10039083 Rhinitis LLT
    12.0 10028735 Nasal congestion LLT
    12.0 10039085 Rhinitis allergic LLT
    12.0 10012727 Diarrhea LLT
    12.0 10028813 Nausea LLT
    12.0 10013946 Dyspepsia LLT
    12.0 10003988 Back pain LLT
    12.0 10003239 Arthralgia LLT
    12.0 10028411 Myalgia LLT
    12.0 10033425 Pain in extremity LLT
    12.0 10041014 Sleepiness LLT
    12.0 10046735 Urticaria LLT
    12.0 10015587 Exanthema LLT
    12.0 10037087 Pruritus LLT
    12.0 10012485 Dermatitis photosensitive LLT
    12.0 10000357 Accelerated hair loss LLT
    12.0 10033775 Paraesthesia LLT
    12.0 10042772 Syncope LLT
    12.0 10064973 Allergic bronchospasm LLT
    12.0 10001736 Allergic vasculitis LLT
    12.0 10053354 Blood pressure orthostatic abnormal LLT
    12.0 10063927 Orthostatic intolerance LLT
    12.0 10000188 Abnormal weight gain LLT
    12.0 10030095 Oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004502-26 Sponsor Protocol Number: DL/HL/09/18 Start Date*: 2019-07-18
    Sponsor Name:Przedsiębiorstwo Produkcji Farmaceutycznej (P.P.F.)HASCO-LEK S.A.
    Full Title: "Randomized, double-blind, cross-over efficacy and safety study based on the pharmacodynamic model of topical use of the new combination gel containing diphenhydramine hydrochloride 20 mg/g and lid...
    Medical condition: Skin inflamatory and allergic lesions inducted by insects bites (i.e. mosquitos) and after contact with plants (i.e.urtica). Decreasing redness, edema, papular urticaria, analgesic, antipriuritic a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10038198 Redness LLT
    20.0 10018065 - General disorders and administration site conditions 10014210 Edema LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10033474 Pain of skin PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10018069 General pruritus LLT
    20.0 10018065 - General disorders and administration site conditions 10061218 Inflammation PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10015150 Erythema PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000252-28 Sponsor Protocol Number: SHCVOLT1 Start Date*: 2009-03-13
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplanta...
    Medical condition: Patients who have undergone liver transplantation and are infected with Hepatitis C virus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052779 Transplant rejections HLT
    9.1 10024970 Respiratory tract infections HLGT
    9.1 10046577 Urinary tract infections HLT
    9.1 10001032 Acute pyelonephritis LLT
    9.1 10040072 Septicaemia LLT
    9.1 10019972 Herpes viral infections HLT
    9.1 10028440 Mycobacterial infectious disorders HLGT
    9.1 10015107 Epstein-Barr viral infections HLT
    9.1 10011831 Cytomegalovirus infection LLT
    9.1 10019974 Herpes zoster LLT
    9.1 10058872 Fungal sepsis LLT
    9.1 10040808 Skin cancer PT
    9.1 10051358 Post transplant lymphoproliferative disorder LLT
    9.1 10043555 Thrombocytopenias HLT
    9.1 10037561 Purpura thrombocytopenic LLT
    9.1 10002034 Anaemia PT
    9.1 10018932 Haemolytic uraemic syndrome PT
    9.1 10024384 Leukopenia PT
    9.1 10029355 Neutropenias HLT
    9.1 10033661 Pancytopenia PT
    9.1 10013505 Disturbance of liver function tests LLT
    9.1 10002218 Anaphylaxis LLT
    9.1 10002425 Angioedemas HLT
    9.1 10015665 Exfoliative dermatitis LLT
    9.1 10020764 Hypersensitivity vasculitis LLT
    9.1 10021015 Hypokalaemia PT
    9.1 10021058 Hypophosphataemia PT
    9.1 10020603 Hypercholesterolaemia PT
    9.1 10020635 Hyperglycaemia PT
    9.1 10020869 Hypertriglyceridaemia PT
    9.1 10043071 Tachycardia PT
    9.1 10034474 Pericardial effusion PT
    9.1 10048642 Lymphocele PT
    9.1 10051055 Deep vein thrombosis PT
    9.1 10037377 Pulmonary embolism PT
    9.1 10025282 Lymphoedema PT
    9.1 10035742 Pneumonitis PT
    9.1 10035598 Pleural effusion PT
    9.1 10015090 Epistaxis PT
    9.1 10037394 Pulmonary haemorrhage PT
    9.1 10000081 Abdominal pain PT
    9.1 10012735 Diarrhoea PT
    9.1 10042128 Stomatitis PT
    9.1 10033645 Pancreatitis PT
    9.1 10000496 Acne PT
    9.1 10037844 Rash PT
    9.1 10003239 Arthralgia PT
    9.1 10031264 Osteonecrosis PT
    9.1 10037032 Proteinuria PT
    9.1 10029164 Nephrotic syndrome PT
    9.1 10030124 Oedema peripheral PT
    9.1 10021519 Impaired healing PT
    9.1 10030095 Oedema PT
    9.1 10037660 Pyrexia PT
    9.1 10005630 Blood lactate dehydrogenase increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001749-15 Sponsor Protocol Number: ARC005 Start Date*: 2019-05-21
    Sponsor Name:Aimmune Therapeutics , Inc.
    Full Title: Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003665-34 Sponsor Protocol Number: INP20-01 Start Date*: 2019-04-26
    Sponsor Name:InnoUP Farma SL
    Full Title: A multicenter double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral formulation for treatment of...
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000913-19 Sponsor Protocol Number: BILA-3818/PD Start Date*: 2018-05-11
    Sponsor Name:FAES FARMA, S.A.
    Full Title: Phase IV, single centre, randomised, open-label, two-period, two-way crossover clinical trial to assess the efficacy of Bilastine 20mg in the suppression of wheal and flare induced by intradermal h...
    Medical condition: ALLERGIC RHINOCONJUNTIVIS AND CHRONIC URTICARIA
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000790-13 Sponsor Protocol Number: BIL-0115-MED Start Date*: 2015-06-10
    Sponsor Name:FAES FARMA, S.A.
    Full Title: A single-centre, randomized, double-blind, crossover, single-dose clinical trial to compare bilastine, desloratadine, rupatadine and placebo in the suppression of wheal and flare induced by intrade...
    Medical condition: ALLERGIC RHINOCONJUNTIVITIS AND CHRONIC URTICARIA
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 05:57:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA